Prestige Biologics (A334970) Stock Overview
Specializes in the development and production of biologic agents and biosimilars. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
A334970 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Prestige Biologics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,235.00 |
| 52 Week High | ₩5,370.00 |
| 52 Week Low | ₩2,800.00 |
| Beta | 0.85 |
| 1 Month Change | 8.01% |
| 3 Month Change | -10.14% |
| 1 Year Change | -37.31% |
| 3 Year Change | -13.85% |
| 5 Year Change | n/a |
| Change since IPO | -77.38% |
Recent News & Updates
Is Prestige Biologics (KOSDAQ:334970) A Risky Investment?
Dec 02
Prestige Biologics (KOSDAQ:334970) Is Carrying A Fair Bit Of Debt
Jul 01Here's Why Prestige Biologics (KOSDAQ:334970) Can Afford Some Debt
Feb 25Shareholder Returns
| A334970 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 2.2% | -0.9% | 4.1% |
| 1Y | -37.3% | 50.0% | 65.5% |
Return vs Industry: A334970 underperformed the KR Biotechs industry which returned 50% over the past year.
Return vs Market: A334970 underperformed the KR Market which returned 65.5% over the past year.
Price Volatility
| A334970 volatility | |
|---|---|
| A334970 Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A334970 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A334970's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | pbpharma.co.kr |
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd.
Prestige Biologics Co., Ltd. Fundamentals Summary
| A334970 fundamental statistics | |
|---|---|
| Market cap | ₩251.53b |
| Earnings (TTM) | -₩33.88b |
| Revenue (TTM) | ₩13.36b |
Is A334970 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A334970 income statement (TTM) | |
|---|---|
| Revenue | ₩13.36b |
| Cost of Revenue | ₩25.89b |
| Gross Profit | -₩12.53b |
| Other Expenses | ₩21.35b |
| Earnings | -₩33.88b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -435.75 |
| Gross Margin | -93.78% |
| Net Profit Margin | -253.61% |
| Debt/Equity Ratio | 76.1% |
How did A334970 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/07 05:57 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prestige Biologics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.